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Abstract
Purpose The aim of this study was to compare the prevalence
of suboptimal drug treatment in older patients with and with-
out multidose drug dispensing (MDD).
Methods In 200 hip fracture patients (≥65 years of age), orig-
inally recruited to a randomized controlled study in Sahlgrenska
University Hospital in 2009, quality of drug treatment at study
entry was compared between patients with and without MDD.
Two specialist physicians independently assessed and then
agreed on the quality of the drug treatment of each patient.
Suboptimal drug treatment was defined as ≥1 STOPP (Screen-
ing Tool of Older Persons’ potentially inappropriate Prescrip-
tions) or ≥1 START (Screening Tool to Alert to Right Treat-
ment) outcome assessed as clinically relevant after individual
considerations had been made, i.e. over- or undertreatment
(≥1 inappropriate and ≥1 missing drug, respectively).
Results Patients with MDD (n=100) differed from patients
without MDD (n=100) in several ways, for example by being
older (87.6 vs. 81.5 years) and using more drugs (8.4 vs. 5.9
drugs). The total number (±standard deviation) of inappropri-
ate and/or missing drugs per person was greater in MDD
patients compared with patients without MDD (1.92±1.52
vs. 1.06±1.29, P<0.0001); MDD patients had an additional
0.77 inappropriate drugs and an additional 0.09 missing drugs
per person. The prevalence of suboptimal drug treatment was
greater in patientswithMDD than in thosewithoutMDD (86 vs.
55 %, P<0.0001). Logistic regression revealed that subopti-
mal drug treatment was 8.0 times as common in MDD pa-
tients, after adjustments for age, sex, number of drugs, cogni-
tion, and residence (95 % confidence interval 2.4; 26.9).
Corresponding figures for over- and undertreatment were 2.9
(1.1; 7.4) and 1.8 (0.8; 4.3), respectively.
Conclusions Suboptimal drug treatment, including over- and
undertreatment, is more common in MDD patients than in
patients who receive their drugs via ordinary prescriptions.
The findings confirm safety concerns regarding quality of
drug treatment in MDD patients.
Keywords Drug therapy . Health care quality assessment .
Multidose drug dispensing . Overtreatment . Undertreatment
Introduction
Dose dispensing systems are widespread over the world [1].
However, systematic reviews have shown that scientific evi-
dence is scarce [2, 3]. In fact, evidence on beneficial effects,
such as improved adherence, is inconsistent [4, 5]. On the
contrary, recent research has indicated safety concerns regard-
ing the prescribing of drugs to patients within such systems.
For example, patients with multidose drug dispensing (MDD)
have more drugs in the medication list and the drug treatment
is more often potentially harmful according to general indica-
tors of prescribing quality [6]. Further, there is evidence
suggesting that drug treatment is more seldom reconsidered
in patients withMDD [7]. Indeed, a longitudinal analysis even
indicates a causal relationship, that is, after transition to an
MDD system a distinct and maintained change in drug treat-
ment occurs [8].
If there is a causal relationship between MDD and subop-
timal drug treatment, this is worth attention; the prescriber
rather than the nursing and pharmacy services accounts for the
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majority of severe medication errors [9]. The need for scien-
tific evidence is further emphasized by the fact that MDD is
often used by frail patients who may have a diminished
capacity to speak for themselves, i.e. older people and people
who have difficulties in handling their drugs due to impaired
physical or cognitive function. Moreover, MDD is used by
many patients. In Sweden, for example, 8 % of people aged
≥65 years use such a system [1].
Available evidence does not allow firm conclusions
concerning quality of drug treatment in patients with MDD.
Indeed, to assess quality of prescribing is a delicate matter. In
fact, an extensive medication list and potentially harmful drug
treatment according to general indicators of prescribing qual-
ity do not necessarily imply suboptimal drug treatment. For
example, a large number of drugs may be appropriate at the
individual level as state-of-the-art guidelines for many condi-
tions, including, e.g. cardiovascular disease, imply concurrent
treatment with several drugs. Further, the ability of general
indicators to distinguish between appropriate and inappropri-
ate drug treatment at the individual level has not been
established [10].
An approach to determine quality of drug treatment may be
to use screening tools to identify potential quality problems
and then to confirm or reject these by specialist physician
assessments based on individual considerations for the specif-
ic patient. Indeed, when it comes to characterizing the quality
of drug treatment, a medical assessment at the individual level
is the key step. As for the screening procedure, the validated
screening Tool of Older Persons’ potentially inappropriate
Prescriptions (STOPP) and the Screening Tool to Alert to
Right Treatment (START) may be useful to identify potential-
ly inappropriate and missing drugs, respectively [11].
The aim of this study was to compare the prevalence of
suboptimal drug treatment in older patients with and without
MDD, that is, over- and undertreatment after individual con-
siderations have been made.
Methods
The study complies with the Declaration of Helsinki, and
ethics approval was obtained from the Regional Ethical Re-
view Board in Gothenburg (Dnr 095-09).
In 200 hip fracture patients (≥65 years of age), consecu-
tively recruited to a randomized controlled study in the de-
partments of orthopedics, geriatrics, and medicine at
Sahlgrenska University Hospital in 2009 [12], quality of drug
treatment at study entry (admission to hospital) was compared
between patients with MDD and patients without MDD (con-
trol patients).
One general practitioner (BB) and one geriatrician (AK)
independently assessed the quality of drug treatment in two
steps. First, they identified potentially suboptimal drug
treatment by the use of STOPP and START. These screening
tools provide 65 criteria for potentially inappropriate drugs
and 22 criteria for potentially missing drugs, respectively [11].
Then the clinical relevance of identified STOPP and/or
START outcomes was assessed at the individual level. Thus,
STOPP outcomes were assessed as not clinically relevant, i.e.
not representing an inappropriate drug, if the expected benefit
of the medication was judged to outweigh the potential harm,
such as neuroleptic treatment in a patient with schizophrenia.
Correspondingly, STARToutcomes were assessed as not clin-
ically relevant, i.e., not representing a missing drug, if there
was a clinical reason, such as an adverse drug reaction or a
contraindication, not to treat the patient with the drug. In a
final consensus discussion, the two specialist physicians
reached agreement on all STOPP/START outcomes, and the
clinical relevance of these. In order to keep a conservative
approach to categorizing drugs as inappropriate or missing,
we chose to categorize STOPP and START outcomes not
possible to assess concerning clinical relevance as not clini-
cally relevant.
Suboptimal drug treatment was defined as ≥1 STOPP or ≥1
START outcome assessed as clinically relevant after individ-
ual considerations had been made. Correspondingly, over-
treatment was defined as ≥1 clinically relevant STOPP out-
come (≥1 inappropriate drug) and undertreatment as ≥1 clin-
ically relevant START outcome (≥1 missing drug). If no
clinically relevant STOPP or START outcomes were present,
the drug treatment was considered appropriate.
All drug treatment assessments were based on information
in the medical records, including laboratory data, from hospi-
tal and primary care. These records were available due to the
design of the original randomized controlled study. Further,
baseline data from the original study were used, including
information on risk of falls, cognition, residence, and kidney
function [12]. The latter, estimated with the Cockcroft-Gault
equation, was dichotomized as either ≥50 or <50 ml/min to fit
the STOPP and START criteria.
Statistics
The statistical analyses were performed using SPSS 17.0
(SPSS, Chicago, IL, USA). The Mann-Whitney and the chi-
square tests were used for comparisons between MDD and
control patients. Kappa statistics was used to assess inter-rater
agreement. Logistic regression was performed to evaluate the
association between MDD and suboptimal drug treatment as
well as over- and undertreatment. The results were adjusted
for age, sex, number of drugs (as a proxy for burden of
disease), cognition (defined as impaired including dementia
or not), and residence (defined as nursing home or not). With
100 patients in each group and an expected prevalence of
suboptimal drug treatment of 60 % in control patients, the
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study had a power of >80 % to detect that the corresponding
prevalence in MDD patients was 33 % greater.
Results
Characteristics of the patients are presented in Table 1. Com-
pared with control patients (n=100), MDD patients (n=100)
were older and treated with more drugs. Further, their cogni-
tion and kidney function were more often impaired. They also
lived in nursing homes to a greater extent.
The prevalence of STOPP/START outcomes as well as
suboptimal drug treatment is presented in Table 2. The kappa
value of the inter-rater agreement for STOPP and START
outcomes was 0.52.
In MDD and control patients, 147 out of 208 (70.7 %) and
70 out of 97 (72.2 %) STOPP outcomes were assessed as
clinically relevant. For START outcomes, the corresponding
figures were 45 out of 157 (28.7 %) and 36 out of 93 (38.7 %),
respectively. MDD patients had an additional 0.77 inappro-
priate drugs and 0.09 missing drugs. Suboptimal drug treat-
ment was more frequent in MDD patients than in control
patients (86 vs. 55 %, P<0.0001). The corresponding figures
for over- and undertreatment were 75 vs. 43 % (P<0.0001)
and 37 vs. 28 % (P=0.17), respectively.
The odds for suboptimal drug treatment were 8.0
times greater in MDD patients after adjustments for
age, sex, number of drugs, cognition, and residence
(95 % confidence interval (CI) 2.4; 26.9). The corre-
sponding odds for over- and undertreatment were 2.9
(1.1; 7.4) and 1.8 (0.8; 4.3), respectively.
In Table 3, suboptimal drug treatment is described. Com-
mon overtreatment included (i) benzodiazepines, neurolep-
tics, and long-term opiates in those prone to falls, (ii) aspirin
without an apparent indication, and (iii) loop-diuretics without
clinical signs of heart failure. Common undertreatment includ-
ed history of cardiovascular disease without recommended
secondary prevention.
Discussion
In the present study, we show that suboptimal drug treatment,
that is, over- and/or undertreatment, is more common inMDD
patients compared with patients who receive their drugs via
ordinary prescriptions. Indeed, MDD patients had an addition-
al 0.77 inappropriate drugs and an additional 0.09 drugs that
were missing but considered important. Further, after differ-
ences in characteristics between the patient groups had been
considered, MDD patients ran an eight-fold increased risk for
suboptimal drug treatment, a three-fold increased risk for
overtreatment, and a two-fold increased risk for
undertreatment. Thus, our findings suggest that MDD is a
prominent determinant for suboptimal drug treatment. This
finding is particularly interesting since MDD has been intro-
duced to facilitate and increase safety in drug handling for the
patient and the health care. Indeed, new technology which
aims to solve a problem may introduce new problems [13].
In the present study, overtreatment was more prevalent than
undertreatment. This may not be surprising since MDD pa-
tients are treated with numerous drugs [6, 8], many of which
are psychotropics, a drug class which is considered hard to
withdraw [14]. However, the proportion of STOPP outcomes
being clinically relevant was quite similar between MDD and
control patients indicating that the results cannot be explained
by differences in suitability of the criteria between patients
with and without MDD.
Interestingly, undertreatment was more common in MDD
patients although these patients had an additional 2.5 drugs per
patient compared with control patients. However, the lower
confidence limit passed the line of unity. The proportion of
START outcomes being clinically relevant was greater in con-
trol than inMDD patients. This may be explained by the higher
age of MDD patients. Indeed, initiation of preventive treatment
can be questioned with a short expected survival time.
Some previous studies indicate that an MDD system in-
cluding medication records may provide a better overview of
the patients’ medication lists and reduce medication errors
[15–17]. In addition, the initiation of MDD may be preceded
by a medication review in order to improve drug treatment
quality [18]. In the Swedish MDD system, medication records
are provided as well as computerized checks for drug interac-
tions [19]. Thus, our findings that MDD is associated with
suboptimal drug treatment may be surprising, and underlying
mechanisms need to be speculated upon.
First, MDD implies that all dispensable tablets which
should be ingested concomitantly are delivered in machine-
dispensed unit bags. This procedure may reduce patients’
knowledge of drugs [4], and consequently their attentiveness
to effects and adverse reactions for specific drugs. The same
may apply to care-takers and relatives. Indeed, nurses have
been reported to lose knowledge regarding patients’ medica-
tions upon introduction of an MDD system [16]. This may
Table 1 Characteristics ofMDD and control patients. Values are given as
counts (which correspond to percentages) or mean±standard deviation
MDD, n=100 Control, n=100 P value
Age, years 87.6±5.4 81.5±7.2 <0.0001




Nursing home resident 55 5 <0.0001
eGFR <50 ml/min 59 33 0.0002
Number of drugs 8.4±3.6 5.9±3.8 <0.0001
eGFR estimated glomerular filtration rate, MDD multidose drug
dispensing
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make nurses less involved in drug treatment and less capable
of picking up drug-related symptoms. Taken together, a re-
duced level of knowledge in key persons may have an impact
on the quality of drug treatment.
Second, the medication record used for drugs prescribed
within an MDD system may differ from that of drugs pre-
scribed the usual way in healthcare. In such systems, the
prescriber has to document drug treatment in both systems
Table 2 Prevalence of STOPP/START outcomes as well as suboptimal drug treatment in MDD (n=100) and control (n=100) patients. In (A), mean
number of outcomes/drugs is presented (± standard deviation). In (B), number of patients is presented (which corresponds to percentages)
MDD Control P value
A
STOPP/START outcomes 3.65±1.94 1.90±1.64 <0.0001
STOPP outcomes 2.08±1.48 0.97±1.19 <0.0001
START outcomes 1.57±1.34 0.93±1.01 0.0004
Inappropriate/missing drugs (clinically relevant STOPP/START outcomes) 1.92±1.52 1.06±1.29 <0.0001
Inappropriate drugs (clinically relevant STOPP outcomes) 1.47±0.70 0.70±1.09 <0.0001
Missing drugs (clinically relevant START outcomes) 0.45±0.64 0.36±0.64 0.20
B
≥1 STOPP/START outcome 97 73 <0.0001
≥1 STOPP outcome 86 54 <0.0001
≥1 START outcome 77 58 0.004
Suboptimal drug treatment (≥1 clinically relevant STOPP/START outcome) 86 55 <0.0001
Overtreatment (≥1 clinically relevant STOPP outcome) 75 43 <0.0001
Undertreatment (≥1 clinically relevant START outcome) 37 28 0.17
MDDmultidose drug dispensing, START, Screening Tool to Alert to Right Treatment, STOPP Screening Tool of Older Person’s potentially inappropriate
Prescription
Table 3 Suboptimal drug treatment, including inappropriate and missing drugs, identified in ≥5 patients. Values are presented as number of patients
(which corresponds to percentages)
MDD, n=100 Control, n=100
Benzodiazepines in those prone to falls I 32 15
Aspirin at dose >150 mg day I 16 7
Loop diuretic for dependent ankle oedema only, i.e. no clinical signs of heart failure I 15 5
Aspirin with no history of coronary, cerebral or peripheral arterial symptoms, or occlusive arterial event I 6 7
Long-term long-acting benzodiazepines I 6 7
Neuroleptic drugs in those prone to falls I 10 1
Beta-blocker with chronic stable angina M 6 4
Vasodilator drugs known to cause hypotension in those with persistent postural hypotension I 5 4
Long-term opiates in those with recurrent falls I 8 1
Aspirin or clopidogrel with a documented history of atherosclerotic coronary, cerebral,
or peripheral vascular disease in patients with sinus rhythm
M 6 3
Statin therapy with a documented history of coronary, cerebral, or peripheral vascular disease, where the
patient’s functional status remains independent for activities of daily living and life expectancy is >5 years
M 3 6
Prolonged use of first generation antihistamines I 6 1
Warfarin in the presence of chronic atrial fibrillation M 5 2
Oestrogens without progestogen in patients with intact uterus I 4 2
First generation antihistamines in those prone to falls I 5 0
Duplicate drug classes I 4 1
ACE inhibitor with chronic heart failure M 4 1
Bisphosphonates in patients taking maintenance oral corticosteroid therapy M 3 2
ACE angiotensin converting enzyme, I inappropriate drug,M missing drug, MDD multidose drug dispensing, START Screening Tool to Alert to Right
Treatment, STOPP Screening Tool of Older Person’s potentially inappropriate Prescription
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[20] and may experience an increased workload [16, 17]. This
may affect prescribing practices and reduce reconsideration of
drug treatment, and consequently have an effect on treatment
quality. Further, such systems may increase the risk of medi-
cation errors [19–21].
Third, another explanation for suboptimal drug treatment
inMDD patients is that the conditions of these patients may be
more multifaceted and thus involve more treatment difficul-
ties, illustrated by the variety of clinically relevant STOPP and
START outcomes identified. Indeed, the severity and the
multiplicity of diseases may have an impact on the prevalence
of over- and undertreatment.
Strengths and weaknesses
The most important strength of the present study is that we
have made individual considerations when evaluating the
quality of drug treatment. Indeed, previous studies have used
general indicators to distinguish between appropriate and
suboptimal treatment, and these may not be applicable at the
individual level. Further, with our approach, a major concern
of previous studies, confounding by indication, is diminished.
In fact, when evaluating inappropriate and missing drug treat-
ment in register-based studies, differences between patients
with and without MDD may be hard to control for.
Another strength is that suboptimal drug treatment includ-
ed both over- and undertreatment. This approach gives a more
comprehensive picture of the quality of the drug treatment as
compared to previous studies which focus on overtreatment
[6, 8]. The inter-rater agreement was moderate, indicating that
some subjectivity is involved in the assessments of STOPP
and START. This is not surprising since a clinical assessment
is, at least partly, a matter of opinion. Nevertheless, consensus
could be reached in all cases.
The fact that we have analyzed hip fracture patients implies
both strengths and weaknesses. Indeed, these patients may
represent a relevant subgroup of older patients since hip
fracture is a common and serious diagnosis in Sweden, where
every fourth middle-aged woman will sustain a hip fracture
during her lifetime, one out of three hip fracture patients is a
man, and the mortality rate within 6 months after the fracture
is 20 % [22]. Further, these patients are treated with many
medications [23] and many of them use MDD [7]. In fact,
evaluating drug treatment quality in hip fracture patients may
make the differences between MDD and control patients
smaller than could be expected in the general population,
where patients without MDD can be expected to be healthier.
Nevertheless, the prevalence of over- and undertreatment,
especially those involving fall risk, may differ from those
found in a general population of older people.
A limitation of the present study is the cross-sectional study
design, which does not allow conclusions concerning causal-
ity between MDD and suboptimal drug treatment. Thus, we
cannot rule out if MDD leads to suboptimal drug treatment, or
if such drug treatment leads to MDD. However, a previous
longitudinal analysis of drug treatment before and after tran-
sition to an MDD system may suggest that the former alter-
native is more probable [8]. Another limitation is that the
assessors were not blinded to the fact as to whether the patient
had MDD or not. This was not practically possible, since
medical records had to be scrutinized. The process of inde-
pendent assessments and consensus, however, may diminish
this problem. Further, although extensive and comprising
in all 87 criteria per patient, STOPP and START may
not capture all forms of over- and undertreatment. Thus,
we cannot exclude other forms of suboptimal drug
treatment. Finally, the generalizability of the results
may be an issue as MDD systems may differ between
countries and continents. However, although the process
of prescribing may vary, the delivery of tablets in unit
bags is a feature in common.
Conclusion
We found that patients with MDD had suboptimal drug treat-
ment to a greater extent than patients who received their drugs
via ordinary prescriptions. Thus, this study confirms that
MDD is associated with safety concerns when it comes to
quality of drug treatment. The results should be of interest for
health care decision-makers and prescribers in countries that
already have, or plan to introduce, dose dispensing systems
and to people who design the prescribing properties within
such systems.
Acknowledgments The study was supported by the Health and Med-
ical Care Committee of the Region Västra Götaland and the Swedish
Research Council. The funding sources did not influence design,
methods, subject recruitment, data collections, analysis, preparation of
paper, or the decision to submit the paper for publication.
Conflicts of interest The authors declare that they have no conflicts of
interest.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Medical Products Agency (2013) Utvärdering av dostjänsten
[Evaluation of dose dispensing] 10
2. Swedish Council on Technology Assessment in Health Care (2009)
How can drug consumption among the elderly be improved? A
Systematic Review 193:12–19. www.sbu.se/upload/Publikationer/
Content1/1/Drug_Consumption_among_Elderly_summary.pdf
Eur J Clin Pharmacol (2014) 70:867–872 871
3. Sinnemaki J, Sihvo S, Isojarvi J, BlomM, Airaksinen M, Mantyla A
(2013) Automated dose dispensing service for primary healthcare
patients: a systematic review. Syst Rev 2:1
4. Kwint HF, Stolk G, Faber A, Gussekloo J, Bouvy ML (2013)
Medication adherence and knowledge of older patients with and
without multidose drug dispensing. Age Ageing 42:620–626
5. Larsen AB, Haugbolle LS (2007) The impact of an automated
dose-dispensing scheme on user compliance, medication un-
derstanding, and medication stockpiles. Res SocAdm Pharm 3:
265–284
6. Sjöberg C, Edward C, Fastbom J, Johnell K, Landahl S, Narbro K,
Wallerstedt SM (2011) Association between multi-dose drug dis-
pensing and quality of drug treatment—a register-based study.
PLoS ONE 6:e26574
7. Sjöberg C, Ohlsson H, Wallerstedt SM (2012) Association between
multi-dose drug dispensing and drug treatment changes. Eur J Clin
Pharmacol 68:1095–1101
8. Wallerstedt SM, Fastbom J, Johnell K, Sjöberg C, Landahl S,
Sundström A (2013) Drug treatment in older people before and after
the transition to a multi-dose drug dispensing system—a longitudinal
analysis. PLoS ONE 8:e67088
9. Bates DW, Boyle DL, Vander Vliet MB, Schneider J, Leape L (1995)
Relationship between medication errors and adverse drug events. J
Gen Intern Med 10:199–205
10. Hoven JL, Haaijer-Ruskamp FM, Vander Stichele RH (2005)
Indicators of prescribing quality in drug utilisation research: report
of a European meeting (DURQUIM, 13-15 May 2004). Eur J Clin
Pharmacol 60:831–834
11. Gallagher PF, O’Connor MN, O’Mahony D (2011) Prevention of
potentially inappropriate prescribing for elderly patients: a random-
ized controlled trial using STOPP/START criteria. Clin Pharmacol
Ther 89:845–854
12. Sjöberg C, Wallerstedt SM (2013) Effects of medication re-
views performed by a physician on treatment with fracture-
preventing and fall-risk-increasing drugs in older adults with
hip fracture—a randomized controlled study. J Am Geriatr Soc
61:1464–1472
13. Hidle U (2007) Implementing technology to improve medication
safety in healthcare facilities: a literature review. JNY State Nurses
Assoc 38:4–9
14. Hedenrud TM, Svensson SA, Wallerstedt SM (2013) “Psychiatry is
not a science like others” - a focus group study on psychotropic
prescribing in primary care. BMC Fam Pract 14:115
15. Wekre LJ, Spigset O, Sletvold O, Sund JK, Grimsmo A (2010)
Multidose drug dispensing and discrepancies between medication
records. Qual Saf Health Care 19:e42
16. Wekre LJ, Melby L, Grimsmo A (2011) Early experiences with the
multidose drug dispensing system—a matter of trust? Scand J Prim
Health Care 29:45–50
17. Wekre LJ, Bakken K, Garasen H, Grimsmo A (2012) GPs’ prescrip-
tion routines and cooperation with other healthcare personnel before
and after implementation of multidose drug dispensing. Scand J
Public Health 40:523–530
18. Sinnemaki J, Saastamoinen LK, Hannula S, Peura S, Airaksinen M
(2013) Starting an automated dose dispensing service provided by
community pharmacies in Finland. Int J Clin Pharm
19. Alassaad A, Gillespie U, Bertilsson M, Melhus H, Hammarlund-
Udenaes M (2013) Prescription and transcription errors in
multidose-dispensed medications on discharge from hospital: an
observational and interventional study. J Eval Clin Pract 19:185–191
20. Midlöv P, Bahrani L, Seyfali M, Höglund P, Rickhag E, Eriksson T
(2012) The effect of medication reconciliation in elderly patients at
hospital discharge. Int J Clin Pharm 34:113–119
21. Bergkvist A, Midlöv P, Höglund P, Larsson L, Bondesson A,
Eriksson T (2009) Improved quality in the hospital discharge sum-
mary reduces medication errors—LIMM: Landskrona Integrated
Medicines Management. Eur J Clin Pharmacol 65:1037–1046
22. Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby AK
(2002) International variations in hip fracture probabilities: implica-
tions for risk assessment. J Bone Miner Res 17:1237–1244
23. Sjöberg C, Bladh L, Klintberg L, Mellström D, Ohlsson C,
Wallerstedt SM (2010) Treatment with fall-risk-increasing and
fracture-preventing drugs before and after a hip fracture: an observa-
tional study. Drugs Aging 27:653–661
872 Eur J Clin Pharmacol (2014) 70:867–872
